Molecular Partners
MOLN
6 hedge funds and large institutions have $13.3M invested in Molecular Partners in 2025 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 0 closing their positions.
0% more funds holding
Funds holding: 6 → 6 (0)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
0.01% less ownership
Funds ownership: 8.88% → 8.87% (-0.01%)
3% less capital invested
Capital invested by funds: $13.7M → $13.3M (-$426K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EWA
EverSource Wealth Advisors
Birmingham,
Alabama
|
+$421 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$18K |
MOLN Hedge Fund Activity: Q3 2025 in Review
6 of the 7,635 institutional investors tracked by Wall St. Rank reported a position in Molecular Partners (MOLN) for Q3 2025, worth a combined $13.3M — down 3.1% from $13.7M a quarter earlier.
Fund positioning in MOLN was balanced in Q3 2025: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 1 trimmed.
The largest buyer was EverSource Wealth Advisors, adding an estimated $421. The largest seller was UBS Group, cutting an estimated $18K.
- 6 institutional investors held Molecular Partners (MOLN) as of Q3 2025, unchanged from Q2 2025.
- Funds reported $13.3M of Molecular Partners stock for Q3 2025, down 3.1% quarter-over-quarter.
- 0 funds opened new Molecular Partners positions in Q3 2025 and 0 closed out.
- The largest Molecular Partners buyer in Q3 2025 was EverSource Wealth Advisors, an estimated $421 added.
- The largest Molecular Partners seller in Q3 2025 was UBS Group, an estimated $18K sold.
Based on aggregated 13F filings for Q3 2025.